Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/rmv.2557 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sertraline modulates hippocampal plasticity via sigma 1 receptors, cellular stress and neurosteroids.
Transl Psychiatry
November 2024
Department of Psychiatry & Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St. Louis, MO, USA.
In addition to modulating serotonin transport, selective serotonin reuptake inhibitors (SSRIs) have multiple other mechanisms that may contribute to clinical effects, and some of these latter actions prompt repurposing of SSRIs for non-psychiatric indications. In a recent study of the SSRIs fluvoxamine, fluoxetine and sertraline we found that, unlike the other two SSRIs, sertraline acutely inhibited LTP at a low micromolar concentration through inverse agonism of sigma 1 receptors (S1Rs). In the present studies, we pursued mechanisms contributing to sertraline modulation of LTP in rat hippocampal slices.
View Article and Find Full Text PDFA circuit from lateral hypothalamic to dorsal hippocampal dentate gyrus modulates behavioral despair in mice.
Cereb Cortex
October 2024
Department of Pharmacology, College of Pharmacy, China Pharmaceutical University, 639 Longmian Road, Jiangning District, Nanjing 211198, China.
Behavioral despair is one of the clinical manifestations of major depressive disorder and an important cause of disability and death. However, the neural circuit mechanisms underlying behavioral despair are poorly understood. In a well-established chronic behavioral despair (CBD) mouse model, using a combination of viral tracing, in vivo fiber photometry, chemogenetic and optogenetic manipulations, in vitro electrophysiology, pharmacological profiling techniques, and behavioral tests, we investigated the neural circuit mechanisms in regulating behavioral despair.
View Article and Find Full Text PDF[The Impact of Antidepressants on COVID-19 and Post-Acute COVID-19 Syndrome: A Scoping-Review Update].
Fortschr Neurol Psychiatr
September 2024
LWL-Universitätsklinikum der Ruhr-Universität Bochum, Klinik für Psychiatrie, Psychotherapie und Präventivmedizin, Bochum, Germany.
Article Synopsis
- The study investigates the potential clinical benefits of antidepressants (AD), specifically fluvoxamine, against COVID-19 and Long COVID, given their preclinical antiviral and anti-inflammatory effects.
- A systematic review of literature identified 1016 articles, including a variety of studies that suggest fluvoxamine significantly reduces COVID-19 infections and severity, particularly when used early in treatment.
- The findings indicate that fluvoxamine may lower mortality and hospitalization rates by 40-70% compared to standard care, with effectiveness linked to higher dosages, while maintaining a low risk of adverse effects similar to placebo.
Author Correction: A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications.
Sci Rep
July 2024
Natural Products for Neuroprotection and Anti‑Ageing (Neur‑Age Natura) Research Unit, Chulalongkorn University, Bangkok, 10330, Thailand.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!